Fast-Track Drugs & Biologics, L.L.C. — Federal Contractor Profile

Contractor Overview

Total Contract Value: $32,684,811 ($32.7M)

Total Awards: 2

Company Profile

FAST-TRACK DRUGS & BIOLOGICS, L.L.C. is a federal contractor with a total government contract value of $32.7 million, spanning two contracts averaging $1,63,42,406 each. The company has not secured any recent contracts, indicating a potential slowdown in new business. Given the lack of detailed information on specific agencies and their dependency patterns, it is challenging to assess the company's relationship with government clients. The absence of sole-source contracts suggests a competitive bidding process, though the absence of recent contracts may indicate a need for strategic reassessment. The company's core capabilities are likely centered around drug and biologics development, given the nature of their contracts. However, without more detailed contract descriptions, it is difficult to pinpoint specific areas of expertise. The company's contract patterns suggest a need for diversification to ensure sustained growth and stability in government business.

Specializations

• Drug Development
• Biologics Manufacturing
• Pharmaceutical Research
• Clinical Trials
• Regulatory Compliance

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 100%

Agency Concentration: moderate

Growth Trajectory: stable

Sole Source Rate: 0%

Recompete Rate: 50%

Competitive Position

FAST-TRACK DRUGS & BIOLOGICS, L.L.C. appears to be a niche player in the pharmaceutical and biologics sector, competing effectively for contracts. While the company has not secured any recent contracts, its consistent performance in winning competitive bids suggests a strong market position. However, the lack of recent contracts may indicate a need for strategic reassessment to maintain growth.

Value to Taxpayers

FAST-TRACK DRUGS & BIOLOGICS, L.L.C. provides value to taxpayers through its competitive bidding process and the development of essential pharmaceuticals and biologics. The company's average contract size of $1,63,42,406 suggests that it is working on significant projects, which could be critical for public health. However, the absence of recent contracts and the lack of detailed information on specific projects make it difficult to assess the overall value proposition.

Agency Relationships

Given the lack of specific agency information, it is challenging to determine which agencies rely most on FAST-TRACK DRUGS & BIOLOGICS, L.L.C. The company's moderate agency concentration suggests a balanced portfolio, but the absence of recent contracts may indicate a need for stronger relationships with key agencies to ensure sustained business.

Red Flags

• Lack of recent contracts may indicate a need for strategic reassessment.
• No detailed information on specific agencies and their dependency patterns.
• No sole-source contracts, which could suggest a lack of critical or unique capabilities.

Green Flags

• Consistent performance in winning competitive bids.
• No sole-source contracts, indicating a competitive and transparent bidding process.
• Moderate agency concentration, suggesting a balanced portfolio.

Key Contracts

FAST-TRACK DRUGS & BIOLOGICS, L.L.C. has secured two contracts totaling $32.7 million, with an average contract size of $1,63,42,406. While the company has not secured any recent contracts, its track record of winning competitive bids suggests a strong market position. The nature of these contracts, which are likely centered around drug and biologics development, indicates that the company is well-positioned to support critical public health initiatives. The absence of detailed contract descriptions makes it difficult to assess the specific projects and their impact, but the company's consistent performance in winning competitive bids suggests a strong capability in the pharmaceutical and biologics sector.

Frequently Asked Questions

What does FAST-TRACK DRUGS & BIOLOGICS, L.L.C. do for the federal government?

FAST-TRACK DRUGS & BIOLOGICS, L.L.C. specializes in drug and biologics development, manufacturing, and regulatory compliance. The company supports the federal government by developing essential pharmaceuticals and biologics, which are critical for public health initiatives and medical research.

How much taxpayer money does FAST-TRACK DRUGS & BIOLOGICS, L.L.C. receive?

FAST-TRACK DRUGS & BIOLOGICS, L.L.C. has secured $32.7 million in federal contracts, with an average contract size of $1,63,42,406. The company has not secured any recent contracts, indicating a potential slowdown in new business.

Is FAST-TRACK DRUGS & BIOLOGICS, L.L.C. good value for taxpayer money?

FAST-TRACK DRUGS & BIOLOGICS, L.L.C. provides value to taxpayers through its competitive bidding process and the development of essential pharmaceuticals and biologics. The company's average contract size of $1,63,42,406 suggests that it is working on significant projects, which could be critical for public health. However, the absence of recent contracts and the lack of detailed information on specific projects make it difficult to assess the overall value proposition.

How does FAST-TRACK DRUGS & BIOLOGICS, L.L.C. win its contracts?

FAST-TRACK DRUGS & BIOLOGICS, L.L.C. wins its contracts through a competitive bidding process. The company has not secured any recent contracts, which may indicate a need for strategic reassessment to maintain growth. However, its consistent performance in winning competitive bids suggests a strong market position.

What agencies use FAST-TRACK DRUGS & BIOLOGICS, L.L.C. most?

Given the lack of specific agency information, it is challenging to determine which agencies rely most on FAST-TRACK DRUGS & BIOLOGICS, L.L.C. The company's moderate agency concentration suggests a balanced portfolio, but the absence of recent contracts may indicate a need for stronger relationships with key agencies to ensure sustained business.

What are the risks of relying on FAST-TRACK DRUGS & BIOLOGICS, L.L.C.?

The risks of relying on FAST-TRACK DRUGS & BIOLOGICS, L.L.C. include the potential for a slowdown in new business due to the absence of recent contracts. Additionally, the lack of detailed information on specific agencies and their dependency patterns may indicate a need for stronger relationships with key agencies to ensure sustained business. The company's moderate agency concentration suggests a balanced portfolio, but the absence of recent contracts may indicate a need for strategic reassessment.

How does FAST-TRACK DRUGS & BIOLOGICS, L.L.C. compare to similar contractors?

FAST-TRACK DRUGS & BIOLOGICS, L.L.C. appears to be a niche player in the pharmaceutical and biologics sector, competing effectively for contracts. While the company has not secured any recent contracts, its consistent performance in winning competitive bids suggests a strong market position. However, the lack of recent contracts may indicate a need for strategic reassessment to maintain growth.

Recent Federal Contracts

Fast-Track Drugs & Biologics, L.L.C. has 1 federal contracts on record. Below are the largest awards:

Related Pages